Druck Icon

Eckert & Ziegler AG expands Board of Directors / Successful delivery of large-scale production facility

Berlin, 9 December 2004. The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700) has appointed Dr. Andreas Hey (45), a physician, as the third member of the company's Board of Directors, effective as of 1 January 2005. He will be responsible for the Industry & Nuclear Imaging segment, and thus the part of the Pankow-based medical technology company that has thus far generated slightly more than half of Group sales. The Therapy segment, which has shown a strong increase in sales recently and whose products are designed primarily for radiation therapy, will continue to be led by medical physicist Dr. Edgar Löffler.

Dr. Hey previously held the position of managing director of Isotope Products Europe in Waldburg (Baden-Württemberg), a subsidiary of Eckert & Ziegler AG which recently switched from majority-held to wholly-owned status. Before that, he worked as managing director of NEMOD Biotherapeutics GmbH & Co. KG and as an investment manager, independent consultant, and product manager for a number of companies in the life sciences sector.

Successful delivery

Coinciding with the end of the year, and considerably before the planned delivery date, Eckert & Ziegler subsidiary EUROTOPE Entwicklungsgesellschaft für Isotopentechnologien mbH has now delivered its second large-scale facility to the USA at a value of over one million USD. Following comprehensive trial runs, this production cell for a therapeutic radioactive component was accepted by the customer on-site with no reservations.

The Board of Directors